Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.68 [0.55, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | crucial | - |
DOR | 0.68 [0.55, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 4.06 [0.94, 17.43] | | > 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 1.95 [0.54, 7.01] | | < 1 | | 0% | 1 study (1/-) | 15.4 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.94 [0.63, 1.40] | | < 1 | | 0% | 1 study (1/-) | 61.3 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 2.17 [1.28, 3.67] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 1.64 [0.90, 2.99] | | < 1 | | 0% | 1 study (1/-) | 5.3 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 1.36 [0.28, 6.47] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 1.39 [0.06, 31.06] | | < 1 | | 0% | 1 study (1/-) | 41.8 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 8.58 [0.50, 146.20] | | < 1 | | 0% | 1 study (1/-) | 7.1 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 5.01 [0.65, 38.48] | | < 1 | | 0% | 1 study (1/-) | 6.2 % | NA | not evaluable | | non important | - |
Endocrine disorders TRAE (grade 3-4) | 2.80 [0.15, 53.28] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 8.05 [1.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 2.2 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 0.69 [0.02, 20.81] | | < 1 | | 0% | 1 study (1/-) | 58.2 % | NA | not evaluable | | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 0.46 [0.10, 2.07] | | < 1 | | 0% | 1 study (1/-) | 84.4 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 1.39 [0.06, 31.06] | | < 1 | | 0% | 1 study (1/-) | 41.8 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.69 [0.02, 20.81] | | < 1 | | 0% | 1 study (1/-) | 58.2 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 0.17 [0.02, 1.91] | | < 1 | | 0% | 1 study (1/-) | 92.3 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 1.39 [0.06, 31.06] | | < 1 | | 0% | 1 study (1/-) | 41.8 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.69 [0.02, 20.81] | | < 1 | | 0% | 1 study (1/-) | 58.2 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 3.51 [0.19, 64.62] | | < 1 | | 0% | 1 study (1/-) | 20.2 % | NA | not evaluable | | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 6.38 [0.37, 110.82] | | < 1 | | 0% | 1 study (1/-) | 10.4 % | NA | not evaluable | | non important | - |
Vitiligo TRAE (grade 3-4) | 0.35 [0.01, 17.55] | | < 1 | | 0% | 1 study (1/-) | 69.8 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.29 [0.09, 0.87] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.33 [0.14, 0.78] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 1.04 [0.11, 10.11] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.69 [0.02, 20.81] | | < 1 | | 0% | 1 study (1/-) | 58.2 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.51 [0.14, 1.85] | | < 1 | | 0% | 1 study (1/-) | 84.6 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 6.13 [0.81, 46.56] | | < 1 | | 0% | 1 study (1/-) | 4.0 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.80 [0.30, 2.14] | | < 1 | | 0% | 1 study (1/-) | 67.0 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.68 [0.56, 5.04] | | < 1 | | 0% | 1 study (1/-) | 17.6 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 0.46 [0.10, 2.07] | | < 1 | | 0% | 1 study (1/-) | 84.4 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.69 [0.17, 2.80] | | < 1 | | 0% | 1 study (1/-) | 69.8 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.34 [0.05, 2.47] | | < 1 | | 0% | 1 study (1/-) | 85.5 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.81 [0.21, 3.17] | | < 1 | | 0% | 1 study (1/-) | 62.0 % | NA | not evaluable | | non important | - |